Objective. Aminothiols (glutathione (GSH), cysteinylglycine (CG)) may play an important role in the pathogenesis of coronavirus disease 2019 (COVID-19), but the possible association of these indicators with the severity of COVID-19 has not yet been investigated. Methods. The total content (
t
) and reduced forms (
r
) of aminothiols were determined in patients with COVID-19 (
n
=
59
) on admission. Lung injury was characterized by computed tomography (CT) findings in accordance with the CT0-4 classification. Results. Low tGSH level was associated with the risk of severe COVID-19 (
tGSH
≤
1.5
μ
M
, mild vs. moderate/severe:
risk
ratio
RR
=
3.09
,
p
=
0.007
) and degree of lung damage (
tGSH
≤
1.8
μ
M
,
CT
<
2
vs.
CT
≥
2
:
RR
=
2.14
,
p
=
0.0094
). The rGSH level showed a negative association with D-dimer levels (
ρ
=
−
0.599
,
p
=
0.014
). Low rCG level was also associated with the risk of lung damage (
rCG
≤
1.3
μ
M
,
CT
<
2
vs.
CT
≥
2
:
RR
=
2.28
,
p
=
0.001
). Levels of rCG (
ρ
=
−
0.339
,
p
=
0.012
) and especially tCG (
ρ
=
−
0.551
,
p
=
0.004
) were negatively associated with platelet count. In addition, a significant relationship was found between the advanced oxidation protein product level and tGSH in patients with moderate or severe but not in patients with mild COVID-19. Conclusion. Thus, tGSH and rCG can be seen as potential markers for the risk of severe COVID-19. GSH appears to be an important factor to oxidative damage prevention as infection progresses. This suggests the potential clinical efficacy of correcting glutathione metabolism as an adjunct therapy for COVID-19.